Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Q1 2026 results and business updates reported for quarter ended March 31, 2026.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results and business updates reported for quarter ended March 31, 2026
- Full financial details and operating metrics contained in Exhibit 99.1
- May 7, 2026 announcement provides investors the latest quarterly performance update
Item 8.01 · Other Events
- Board-approved repurchase authorization of up to $500 million in common stock
- Potentially supports share price and signals management’s confidence in BBIO’s valuation
- No obligation to repurchase; timing, pricing, and amounts remain at management’s discretion
- Program may be suspended or discontinued, limiting certainty of capital return
- Repurchases expose capital allocation to stock-price volatility and competing investment needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.